JLL Partners, the New York-based private equity firm, completed its acquisition of American Dental Partners, the Massachusetts-based dental group practice with operations in 21 states. Specifics of the deal were not publicized; JLL’s Michael Lagarde, a managing director with the firm, worked on the transaction. PRESS RELEASE: JLL Partners, Inc. (“JLL”) and American Dental Partners, [...]

HealthCor Partners Management, an investor in fast-growing health care and life sciences companies, is out seeking $300 million—a tally that would double the firm’s assets under management if achieved. The New York-based firm is part of the HealthCor Group, a hedge-fund manager and private equity shop with more than $3 billion under management. According to [...]

Patheon, a provider of contract development and manufacturing services to the global pharmaceutical industry, has appointed Michel Lagarde, principal, JLL Partners, to its board of directors. Lagarde replaces Thomas S. Taylor, managing director, JLL Partners, who is leaving the board. PRESS RELEASE Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services [...]

Dental group practice American Dental Partners has announced the expiration of the 40-day “go-shop” period during which the company solicited alternative proposals to the acquisition of the company by JLL Partners. After a broad solicitation of financial and strategic parties during the period, the company did not receive any acquisition proposals. The company expects the [...]

JLL Partners is acquiring American Dental Partners for approximately $398 million, including $81 million in currently outstanding debt. American Dental Partners is a leading business partner to dental group practices. The company is affiliated with 27 dental group practices, which have 282 dental facilities with approximately 2,404 operatories in 21 states. PRESS RELEASE American Dental [...]

The Carlyle Group and Hellman & Friedman’s $3.9 billion agreement to buy Pharmaceutical Product Development Inc. marks the latest example of buyout shops buying companies that run clinical trials for pharma and biotech companies.

These so-called contract research organizations, or CROs, are expected to expand and consolidate, making it highly likely we could see more LBOs. Click through below to see a selection of other noteworthy CROs, presented alphabetically, that could look attractive to sponsors. These include public companies that, like PPD, might find it easier to navigate the market’s consolidation under private ownership; public companies with recent changes at the CEO level; and private equity-owned companies, including one that’s been in its owner’s portfolio for almost four years now.

Friedman Fleischer & Lowe said Wednesday that it has completed its buy of C.H.I. Overhead Doors. Terms of the deal weren’t disclosed. JLL Partners acquired the Arthur, Ill. garage door maker in the in fall of 2004. News of the C.H.I. sale was reported by The Deal in July.

It looks like JLL Partners will be exiting C.H.I. Overhead Doors after nearly seven years.

Friedman Fleischer & Lowe is buying C.H.I. Overhead, a garage door maker, according to Standard & Poor’s LCD. Friedman Fleischer is in the market for a $203.5 million loan to back its by of C.H.I., LCD said. GE Capital and Wells Fargo are financing the deal, Thomson Reuters Loan Pricing Corp. said.

The Deal, which reported the C.H.I sale last week, said the transaction was valued at roughly $290 million.

New York-based private equity shop JLL Partners has completed the sale of its portfolio company PharmaNet Development Group to inVentiv Health Inc. JLL acquired PharmaNet in 2009. inVentiv Health is an affiliate of Thomas H. Lee Partners. PharmaNet provides drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries.

CCMP Capital Advisors is in talks to buy Medpace, a Cincinnati-based contract research organization, two sources said.

The deal is valued at roughly $500 to $600 million, one person says.

Founded in 1992, Medpace provides clinical drug development services for the pharmaceutical and biotech industries. It employs about 1,000 people globally.

The sale of Medpace was not an auction, one banker says. Instead, CCMP has been in exclusive talks to buy Medpace, the source says.